Benzinga | Nov 19, 2021 05:33AM EST

BMO Capital Initiates Coverage On Biogen with Outperform Rating, Announces Price Target of $315

BMO Capital analyst Evan Seigerman initiates coverage on Biogen (NASDAQ:BIIB) with a Outperform rating and announces Price Target of $315.